NanoVibronix announces results from UroShield case series

NanoVibronix (NAOV) announced findings from a recent retrospective case series evaluating the clinical impact and patient experience of the UroShield system. The case series, conducted between September 2023 and January 2025 by researchers at University Hospitals Coventry and Warwickshire Partnership NHS, assessed a small group of patients who used the UroShield device for durations ranging from 12 weeks to 17 months. The series reviewed pre- and post-treatment data on catheter-associated urinary tract infections, catheter blockages, unplanned hospital visits and patient satisfaction. Key Outcomes of the Case Series Included: a 94% average reduction in CAUTIs and catheter blockages; a 92% decrease in unplanned hospital visits; extended intervals between catheter changes, improving patient comfort and quality of life; high patient compliance and satisfaction; and only one patient discontinued due to worsening of pre-existing bladder symptoms.